{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Breast+Cancer&page=37&q=HER2-positive", "query": { "q": "HER2-positive", "condition": "Breast Cancer", "page": 37 }, "page_size": 10 }, "pagination": { "page": 37, "page_size": 10, "total_count": 1133, "total_pages": 114, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Breast+Cancer&page=38&q=HER2-positive&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Breast+Cancer&page=36&q=HER2-positive&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-18T10:17:22.343Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02291913", "title": "Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Everolimus", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" }, { "name": "Tamoxifen", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Anastrozole", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Toremifine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SCRI Development Innovations, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 48, "start_date": "2014-12-18", "completion_date": "2019-01-31", "has_results": true, "last_update_posted_date": "2020-02-17", "last_synced_at": "2026-10-18T10:17:22.343Z", "location_count": 8, "location_summary": "Fort Myers, Florida • Hollywood, Florida • Pensacola, Florida + 5 more", "locations": [ { "city": "Fort Myers", "state": "Florida" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Pensacola", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" }, { "city": "Terre Haute", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02291913" }, { "nct_id": "NCT07407920", "title": "Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anatomic Stage I Breast Cancer AJCC v8", "Anatomic Stage II Breast Cancer AJCC v8", "Early Stage HER2-Positive Breast Carcinoma", "Early Stage Triple-Negative Breast Carcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Hormone Therapy", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Pertuzumab", "type": "BIOLOGICAL" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2025-10-09", "completion_date": "2028-09-30", "has_results": false, "last_update_posted_date": "2026-09-24", "last_synced_at": "2026-10-18T10:17:22.343Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07407920" }, { "nct_id": "NCT00524303", "title": "Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neoplasms, Breast" ], "interventions": [ { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "FEC75", "type": "DRUG" }, { "name": "Lapatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 100, "start_date": "2007-08", "completion_date": "2015-08", "has_results": true, "last_update_posted_date": "2016-11-11", "last_synced_at": "2026-10-18T10:17:22.343Z", "location_count": 23, "location_summary": "Fountain Valley, California • Los Angeles, California • Denver, Colorado + 18 more", "locations": [ { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Hudson", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00524303" }, { "nct_id": "NCT04332588", "title": "Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET/MRI", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HER2-positive Breast Cancer" ], "interventions": [ { "name": "[18F]FMISO PET/MRI imaging", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 25, "start_date": "2022-03-25", "completion_date": "2027-08", "has_results": false, "last_update_posted_date": "2026-08-17", "last_synced_at": "2026-10-18T10:17:22.343Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT04332588" }, { "nct_id": "NCT02326974", "title": "T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HER-2 Positive Breast Cancer", "Breast Cancer", "Stage II Breast Cancer", "Stage III Breast Cancer" ], "interventions": [ { "name": "T-DM1", "type": "DRUG" }, { "name": "Pertuzumab", "type": "DRUG" }, { "name": "Excision of tumor/mastectomy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 164, "start_date": "2015-01", "completion_date": "2028-01", "has_results": true, "last_update_posted_date": "2026-10-02", "last_synced_at": "2026-10-18T10:17:22.343Z", "location_count": 4, "location_summary": "Boston, Massachusetts • Nashville, Tennessee", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02326974" }, { "nct_id": "NCT00140140", "title": "A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Stage IV (Metastatic) Breast Cancer" ], "interventions": [ { "name": "ABI-007", "type": "DRUG" }, { "name": "vinorelbine", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "G-CSF", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2005-08", "completion_date": "2008-02", "has_results": true, "last_update_posted_date": "2019-11-26", "last_synced_at": "2026-10-18T10:17:22.343Z", "location_count": 2, "location_summary": "Duarte, California • Seattle, Washington", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00140140" }, { "nct_id": "NCT00095862", "title": "Vaccine Therapy in Treating Patients With HER2/Neu Positive or Negative Stage IV Breast Cancer or Other HER2/Neu Positive Cancers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "allogeneic GM-CSF-secreting breast cancer vaccine", "type": "BIOLOGICAL" }, { "name": "recombinant interferon alfa", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Wiseman Research Initiatives LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 24, "start_date": "2004-11", "completion_date": null, "has_results": false, "last_update_posted_date": "2018-02-05", "last_synced_at": "2026-10-18T10:17:22.343Z", "location_count": 3, "location_summary": "Glendale, California • Los Angeles, California", "locations": [ { "city": "Glendale", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00095862" }, { "nct_id": "NCT02422641", "title": "Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Breast Cancer", "Leptomeningeal Disease" ], "interventions": [ { "name": "High-dose Methotrexate (8 gm/m2; HD-MTX)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2015-05", "completion_date": "2027-07", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-10-18T10:17:22.343Z", "location_count": 3, "location_summary": "Baltimore, Maryland • St Louis, Missouri • Winston-Salem, North Carolina", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02422641" }, { "nct_id": "NCT07148505", "title": "A Study of Real-world Outcomes Among Patients Treated With Ribociclib", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 373, "start_date": "2024-04-24", "completion_date": "2024-11-07", "has_results": false, "last_update_posted_date": "2025-08-29", "last_synced_at": "2026-10-18T10:17:22.343Z", "location_count": 1, "location_summary": "East Hanover, New Jersey", "locations": [ { "city": "East Hanover", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT07148505" }, { "nct_id": "NCT03530696", "title": "T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HER2-positive Breast Cancer", "Breast Cancer", "Breast Cancer Stage", "Recurrent Breast Cancer", "Metastatic Breast Cancer", "HER2 Positive Breast Carcinoma" ], "interventions": [ { "name": "Palbociclib", "type": "DRUG" }, { "name": "T-DM1", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Arizona", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2018-12-06", "completion_date": "2022-12-22", "has_results": true, "last_update_posted_date": "2024-08-13", "last_synced_at": "2026-10-18T10:17:22.343Z", "location_count": 16, "location_summary": "Tucson, Arizona • Beverly Hills, California • Aurora, Colorado + 12 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03530696" } ] }